Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Premature Termination of a Randomized Controlled Trial on Image-Guided Stereotactic Body Radiotherapy of Metastatic Spinal Cord Compression.

Suppli MH, Munck Af Rosenschold P, Dahl B, Berthelsen AK, Engelholm SA, Pappot H.

Oncologist. 2019 Oct 11. pii: theoncologist.2019-0672. doi: 10.1634/theoncologist.2019-0672. [Epub ahead of print]

2.

Diabetes increases the risk of serious adverse events after re-irradiation of the spine.

Suppli MH, Munck Af Rosenschöld P, Pappot H, Engelholm SA.

Radiother Oncol. 2019 Jul;136:130-135. doi: 10.1016/j.radonc.2019.04.002. Epub 2019 Apr 17.

PMID:
31015114
3.

The dosimetric effect of residual breath-hold motion in pencil beam scanned proton therapy - An experimental study.

Gorgisyan J, Lomax AJ, Rosenschold PMA, Persson GF, Krieger M, Colvill E, Scherman J, Gagnon-Moisan F, Egloff M, Fattori G, Engelholm SA, Weber DC, Perrin R.

Radiother Oncol. 2019 May;134:135-142. doi: 10.1016/j.radonc.2019.01.033. Epub 2019 Feb 14.

PMID:
31005207
4.

Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors.

Astradsson A, Munck Af Rosenschöld P, Poulsgaard L, Ohlhues L, Engelholm SA, Feldt-Rasmussen U, Marsh R, Roed H, Juhler M.

Clin Transl Radiat Oncol. 2019 Feb 7;15:93-98. doi: 10.1016/j.ctro.2019.02.001. eCollection 2019 Feb.

5.

Influence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients.

Munck Af Rosenschold P, Law I, Engelholm S, Engelholm SA, Muhic A, Lundemann MJ, Roed H, Grunnet K, Skovgaard Poulsen H.

Radiother Oncol. 2019 Jan;130:149-155. doi: 10.1016/j.radonc.2018.10.003. Epub 2018 Nov 13.

PMID:
30446316
6.

Theranostic Imaging May Vaccinate against the Therapeutic Benefit of Long Circulating PEGylated Liposomes and Change Cargo Pharmacokinetics.

Børresen B, Henriksen JR, Clergeaud G, Jørgensen JS, Melander F, Elema DR, Szebeni J, Engelholm SA, Kristensen AT, Kjær A, Andresen TL, Hansen AE.

ACS Nano. 2018 Nov 27;12(11):11386-11398. doi: 10.1021/acsnano.8b06266. Epub 2018 Oct 31.

PMID:
30372038
7.

Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma.

Lundemann M, Munck Af Rosenschöld P, Muhic A, Larsen VA, Poulsen HS, Engelholm SA, Andersen FL, Kjær A, Larsson HBW, Law I, Hansen AE.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):603-613. doi: 10.1007/s00259-018-4180-3. Epub 2018 Oct 2.

PMID:
30276440
8.

rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology.

Kelemen LE, Earp M, Fridley BL, Chenevix-Trench G; Australian Ovarian Cancer Study Group, Fasching PA, Beckmann MW, Ekici AB, Hein A, Lambrechts D, Lambrechts S, Van Nieuwenhuysen E, Vergote I, Rossing MA, Doherty JA, Chang-Claude J, Behrens S, Moysich KB, Cannioto R, Lele S, Odunsi K, Goodman MT, Shvetsov YB, Thompson PJ, Wilkens LR, Dörk T, Antonenkova N, Bogdanova N, Hillemanns P, Runnebaum IB, du Bois A, Harter P, Heitz F, Schwaab I, Butzow R, Pelttari LM, Nevanlinna H, Modugno F, Edwards RP, Kelley JL, Ness RB, Karlan BY, Lester J, Orsulic S, Walsh C, Kjaer SK, Jensen A, Cunningham JM, Vierkant RA, Giles GG, Bruinsma F, Southey MC, Hildebrandt MAT, Liang D, Lu K, Wu X, Sellers TA, Levine DA, Schildkraut JM, Iversen ES, Terry KL, Cramer DW, Tworoger SS, Poole EM, Bandera EV, Olson SH, Orlow I, Vestrheim Thomsen LC, Bjorge L, Krakstad C, Tangen IL, Kiemeney LA, Aben KKH, Massuger LFAG, van Altena AM, Pejovic T, Bean Y, Kellar M, Cook LS, Le ND, Brooks-Wilson A, Gronwald J, Cybulski C, Jakubowska A, Lubiński J, Wentzensen N, Brinton LA, Lissowska J, Hogdall E, Engelholm SA, Hogdall C, Lundvall L, Nedergaard L, Pharoah PDP, Dicks E, Song H, Tyrer JP, McNeish I, Siddiqui N, Carty K, Glasspool R, Paul J, Campbell IG, Eccles D, Whittemore AS, McGuire V, Rothstein JH, Sieh W, Narod SA, Phelan CM, McLaughlin JR, Risch HA, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Gentry-Maharaj A, Ramus SJ, Wu AH, Pearce CL, Lee AW, Pike MC, Kupryjanczyk J, Podgorska A, Plisiecka-Halasa J, Sawicki W, Goode EL, Berchuck A; Ovarian Cancer Association Consortium.

Int J Mol Sci. 2018 Aug 21;19(9). pii: E2473. doi: 10.3390/ijms19092473.

9.

The influence on survival of glucocorticoid induced diabetes in cancer patients with metastatic spinal cord compression.

Schultz H, Pedersen-Bjergaard U, Jensen AK, Engelholm SA, Kristensen PL.

Clin Transl Radiat Oncol. 2018 May 17;11:19-25. doi: 10.1016/j.ctro.2018.04.004. eCollection 2018 Jun.

10.

Glucocorticoid-induced diabetes in patients with metastatic spinal cord compression.

Schultz H, Engelholm SA, Harder E, Pedersen-Bjergaard U, Kristensen PL.

Endocr Connect. 2018 May;7(5):719-726. doi: 10.1530/EC-18-0088. Epub 2018 Apr 18.

11.

Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial.

Møller S, Munck Af Rosenschöld P, Costa J, Law I, Poulsen HS, Engelholm SA, Engelholm S.

Radiother Oncol. 2017 Nov;125(2):223-227. doi: 10.1016/j.radonc.2017.09.039. Epub 2017 Oct 17.

PMID:
29054380
12.

A revision of the Tokuhashi revised score improves the prognostic ability in patients with metastatic spinal cord compression.

Morgen SS, Fruergaard S, Gehrchen M, Bjørck S, Engelholm SA, Dahl B.

J Cancer Res Clin Oncol. 2018 Jan;144(1):33-38. doi: 10.1007/s00432-017-2519-y. Epub 2017 Oct 6.

PMID:
28986702
13.

Feasibility of Pencil Beam Scanned Intensity Modulated Proton Therapy in Breath-hold for Locally Advanced Non-Small Cell Lung Cancer.

Gorgisyan J, Munck Af Rosenschold P, Perrin R, Persson GF, Josipovic M, Belosi MF, Engelholm SA, Weber DC, Lomax AJ.

Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1121-1128. doi: 10.1016/j.ijrobp.2017.08.023. Epub 2017 Aug 24.

PMID:
28964587
14.

Impact of beam angle choice on pencil beam scanning breath-hold proton therapy for lung lesions.

Gorgisyan J, Perrin R, Lomax AJ, Persson GF, Josipovic M, Engelholm SA, Weber DC, Munck Af Rosenschold P.

Acta Oncol. 2017 Jun;56(6):853-859. doi: 10.1080/0284186X.2017.1287950. Epub 2017 Feb 22.

PMID:
28464744
15.

Patterns of failure for patients with glioblastoma following O-(2-[18F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiotherapy.

Lundemann M, Costa JC, Law I, Engelholm SA, Muhic A, Poulsen HS, Munck Af Rosenschold P.

Radiother Oncol. 2017 Mar;122(3):380-386. doi: 10.1016/j.radonc.2017.01.002. Epub 2017 Jan 19.

PMID:
28110959
16.

Visual outcome, endocrine function and tumor control after fractionated stereotactic radiation therapy of craniopharyngiomas in adults: findings in a prospective cohort.

Astradsson A, Munck Af Rosenschöld P, Feldt-Rasmussen U, Poulsgaard L, Wiencke AK, Ohlhues L, Engelholm SA, Broholm H, Hansen Møller E, Klose M, Roed H, Juhler M.

Acta Oncol. 2017 Mar;56(3):415-421. doi: 10.1080/0284186X.2016.1270466. Epub 2017 Jan 13.

PMID:
28084862
17.

Prognostic value of 18F-FET PET imaging in re-irradiation of high-grade glioma: Results of a phase I clinical trial.

Moller S, Law I, Munck Af Rosenschold P, Costa J, Poulsen HS, Engelholm SA, Engelholm S.

Radiother Oncol. 2016 Oct;121(1):132-137. doi: 10.1016/j.radonc.2016.08.014. Epub 2016 Sep 9.

PMID:
27622554
18.

A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.

Karlsen MA, Fagö-Olsen C, Høgdall E, Schnack TH, Christensen IJ, Nedergaard L, Lundvall L, Lydolph MC, Engelholm SA, Høgdall C.

Tumour Biol. 2016 Sep;37(9):12619-12626. Epub 2016 Jul 20.

PMID:
27440204
19.

No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.

Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, Hu Q, Szender JB, Minlikeeva A, Joseph JM, Mayor P, Abrams SI, Segal BH, Wallace PK, Soh KT, Zsiros E, Anton-Culver H, Bandera EV, Beckmann MW, Berchuck A, Bjorge L, Bruegl A, Campbell IG, Campbell SP, Chenevix-Trench G, Cramer DW, Dansonka-Mieszkowska A, Dao F, Diergaarde B, Doerk T, Doherty JA, du Bois A, Eccles D, Engelholm SA, Fasching PA, Gayther SA, Gentry-Maharaj A, Glasspool RM, Goodman MT, Gronwald J, Harter P, Hein A, Heitz F, Hillemmanns P, Høgdall C, Høgdall EV, Huzarski T, Jensen A, Johnatty SE, Jung A, Karlan BY, Klapdor R, Kluz T, Konopka B, Kjær SK, Kupryjanczyk J, Lambrechts D, Lester J, Lubiński J, Levine DA, Lundvall L, McGuire V, McNeish IA, Menon U, Modugno F, Ness RB, Orsulic S, Paul J, Pearce CL, Pejovic T, Pharoah P, Ramus SJ, Rothstein J, Rossing MA, Rübner M, Schildkraut JM, Schmalfeldt B, Schwaab I, Siddiqui N, Sieh W, Sobiczewski P, Song H, Terry KL, Van Nieuwenhuysen E, Vanderstichele A, Vergote I, Walsh CS, Webb PM, Wentzensen N, Whittemore AS, Wu AH, Ziogas A, Odunsi K, Chang-Claude J, Goode EL, Moysich KB; Australian Ovarian Cancer Study.

Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):420-424. doi: 10.1158/1055-9965.EPI-16-0631. Epub 2016 Sep 27.

20.

Health-related Quality of Life in Patients with Metastatic Spinal Cord Compression.

Morgen SS, Engelholm SA, Larsen CF, Søgaard R, Dahl B.

Orthop Surg. 2016 Aug;8(3):309-15. doi: 10.1111/os.12253.

21.

Prospective assessment of the quality of life before, during and after image guided intensity modulated radiotherapy for prostate cancer.

Sveistrup J, Mortensen OS, Bjørner JB, Engelholm SA, Munck Af Rosenschöld P, Petersen PM.

Radiat Oncol. 2016 Sep 7;11(1):117. doi: 10.1186/s13014-016-0689-4.

22.

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.

Southey MC, Goldgar DE, Winqvist R, Pylkäs K, Couch F, Tischkowitz M, Foulkes WD, Dennis J, Michailidou K, van Rensburg EJ, Heikkinen T, Nevanlinna H, Hopper JL, Dörk T, Claes KB, Reis-Filho J, Teo ZL, Radice P, Catucci I, Peterlongo P, Tsimiklis H, Odefrey FA, Dowty JG, Schmidt MK, Broeks A, Hogervorst FB, Verhoef S, Carpenter J, Clarke C, Scott RJ, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N, Bolla MK, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Marme F, Burwinkel B, Yang R, Guénel P, Truong T, Menegaux F, Sanchez M, Bojesen S, Nielsen SF, Flyger H, Benitez J, Zamora MP, Perez JI, Menéndez P, Anton-Culver H, Neuhausen S, Ziogas A, Clarke CA, Brenner H, Arndt V, Stegmaier C, Brauch H, Brüning T, Ko YD, Muranen TA, Aittomäki K, Blomqvist C, Bogdanova NV, Antonenkova NN, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Spurdle AB, Investigators K; Australian Ovarian Cancer Study Group, Wauters E, Smeets D, Beuselinck B, Floris G, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Olson JE, Vachon C, Pankratz VS, McLean C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Kristensen V, Alnæs GG, Zheng W, Hunter DJ, Lindstrom S, Hankinson SE, Kraft P, Andrulis I, Knight JA, Glendon G, Mulligan AM, Jukkola-Vuorinen A, Grip M, Kauppila S, Devilee P, Tollenaar RA, Seynaeve C, Hollestelle A, Garcia-Closas M, Figueroa J, Chanock SJ, Lissowska J, Czene K, Darabi H, Eriksson M, Eccles DM, Rafiq S, Tapper WJ, Gerty SM, Hooning MJ, Martens JW, Collée JM, Tilanus-Linthorst M, Hall P, Li J, Brand JS, Humphreys K, Cox A, Reed MW, Luccarini C, Baynes C, Dunning AM, Hamann U, Torres D, Ulmer HU, Rüdiger T, Jakubowska A, Lubinski J, Jaworska K, Durda K, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Swerdlow A, Ashworth A, Orr N, Jones M, González-Neira A, Pita G, Alonso MR, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, Simard J, Dumont M, Soucy P, Eeles R, Muir K, Wiklund F, Gronberg H, Schleutker J, Nordestgaard BG, Weischer M, Travis RC, Neal D, Donovan JL, Hamdy FC, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Schaid DJ, Kelley JL, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Butterbach K, Park J, Kaneva R, Batra J, Teixeira MR, Kote-Jarai Z, Olama AA, Benlloch S, Renner SP, Hartmann A, Hein A, Ruebner M, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambretchs S, Doherty JA, Rossing MA, Nickels S, Eilber U, Wang-Gohrke S, Odunsi K, Sucheston-Campbell LE, Friel G, Lurie G, Killeen JL, Wilkens LR, Goodman MT, Runnebaum I, Hillemanns PA, Pelttari LM, Butzow R, Modugno F, Edwards RP, Ness RB, Moysich KB, du Bois A, Heitz F, Harter P, Kommoss S, Karlan BY, Walsh C, Lester J, Jensen A, Kjaer SK, Høgdall E, Peissel B, Bonanni B, Bernard L, Goode EL, Fridley BL, Vierkant RA, Cunningham JM, Larson MC, Fogarty ZC, Kalli KR, Liang D, Lu KH, Hildebrandt MA, Wu X, Levine DA, Dao F, Bisogna M, Berchuck A, Iversen ES, Marks JR, Akushevich L, Cramer DW, Schildkraut J, Terry KL, Poole EM, Stampfer M, Tworoger SS, Bandera EV, Orlow I, Olson SH, Bjorge L, Salvesen HB, van Altena AM, Aben KK, Kiemeney LA, Massuger LF, Pejovic T, Bean Y, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Górski B, Gronwald J, Menkiszak J, Høgdall CK, Lundvall L, Nedergaard L, Engelholm SA, Dicks E, Tyrer J, Campbell I, McNeish I, Paul J, Siddiqui N, Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, Cai H, Shu XO, Teten RT, Sutphen R, McLaughlin JR, Narod SA, Phelan CM, Monteiro AN, Fenstermacher D, Lin HY, Permuth JB, Sellers TA, Chen YA, Tsai YY, Chen Z, Gentry-Maharaj A, Gayther SA, Ramus SJ, Menon U, Wu AH, Pearce CL, Van Den Berg D, Pike MC, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Moes-Sosnowska J, Kupryjanczyk J, Pharoah PD, Song H, Winship I, Chenevix-Trench G, Giles GG, Tavtigian SV, Easton DF, Milne RL.

J Med Genet. 2016 Dec;53(12):800-811. doi: 10.1136/jmedgenet-2016-103839. Epub 2016 Sep 5.

23.

Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation ((18)F-FDG, (64)Cu-ATSM and (18)F-FLT) in a Dog with Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring.

Zornhagen KW, Clausen MM, Hansen AE, Law I, McEvoy FJ, Engelholm SA, Kjær A, Kristensen AT.

Diagnostics (Basel). 2015 Sep 11;5(3):372-82. doi: 10.3390/diagnostics5030372.

24.

Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.

French JD, Johnatty SE, Lu Y, Beesley J, Gao B, Kalimutho M, Henderson MJ, Russell AJ, Kar S, Chen X, Hillman KM, Kaufmann S, Sivakumaran H, O'Reilly M, Wang C, Korbie DJ; Australian Ovarian Cancer Study Group; Australian Ovarian Cancer Study, Lambrechts D, Despierre E, Van Nieuwenhuysen E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching PA, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Pisterer J, Hillemanns P, Nakanishi T, Yatabe Y, Goodman MT, Lurie G, Matsuno RK, Thompson PJ, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan JM, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut JM, Iversen E, Weber RP, Brennan D, Berchuck A, Pharoah P, Harnett P, Norris MD, Haber M, Goode EL, Lee JS, Khanna KK, Meyer KB, Chenevix-Trench G, deFazio A, Edwards SL, MacGregor S; Ovarian Cancer Association Consortium.

Oncotarget. 2016 Feb 9;7(6):6353-68. doi: 10.18632/oncotarget.7047.

25.

Employment and sick leave in patients with prostate cancer before, during and after radiotherapy.

Sveistrup J, Mortensen OS, Rosenschöld PM, Engelholm SA, Petersen PM.

Scand J Urol. 2016 Jun;50(3):164-9. doi: 10.3109/21681805.2015.1119190. Epub 2016 Jan 12.

PMID:
26754420
26.
27.
28.

A Retrospective Evaluation of the Benefit of Referring Pediatric Cancer Patients to an External Proton Therapy Center.

Munck af Rosenschold P, Engelholm SA, Brodin PN, Jørgensen M, Grosshans DR, Zhu RX, Palmer M, Crawford CN, Mahajan A.

Pediatr Blood Cancer. 2016 Feb;63(2):262-9. doi: 10.1002/pbc.25768. Epub 2015 Sep 23.

PMID:
26397177
29.

Early changes in perfusion of glioblastoma during radio- and chemotherapy evaluated by T1-dynamic contrast enhanced magnetic resonance imaging.

Møller S, Lundemann M, Law I, Poulsen HS, Larsson HB, Engelholm SA.

Acta Oncol. 2015;54(9):1521-8. doi: 10.3109/0284186X.2015.1063777. Epub 2015 Jul 23.

PMID:
26203926
30.

Survival outcomes in patients with cervical cancer after inclusion of PET/CT in staging procedures.

Hansen HV, Loft A, Berthelsen AK, Christensen IJ, Høgdall C, Engelholm SA.

Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1833-9. doi: 10.1007/s00259-015-3113-7. Epub 2015 Jul 22.

PMID:
26194714
31.

Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma.

Munck Af Rosenschold P, Costa J, Engelholm SA, Lundemann MJ, Law I, Ohlhues L, Engelholm S.

Neuro Oncol. 2015 May;17(5):757-63. doi: 10.1093/neuonc/nou316. Epub 2014 Dec 23.

32.

Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study.

Clausen MM, Hansen AE, Lundemann M, Hollensen C, Pommer T, Munck Af Rosenschöld P, Kristensen AT, Kjær A, McEvoy FJ, Engelholm SA.

Radiat Oncol. 2014 Oct 16;9:228. doi: 10.1186/s13014-014-0228-0.

33.

[Canine cancer patients are included in translational research].

Børresen B, Clausen MM, Hansen AE, Zornhagen KW, Kristensen AT, Engelholm SA, Kjær A.

Ugeskr Laeger. 2014 Jul 7;176(28):V01130041. Review. Danish.

PMID:
25291999
34.

Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.

Kelemen LE, Terry KL, Goodman MT, Webb PM, Bandera EV, McGuire V, Rossing MA, Wang Q, Dicks E, Tyrer JP, Song H, Kupryjanczyk J, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Timorek A, Menon U, Gentry-Maharaj A, Gayther SA, Ramus SJ, Narod SA, Risch HA, McLaughlin JR, Siddiqui N, Glasspool R, Paul J, Carty K, Gronwald J, Lubiński J, Jakubowska A, Cybulski C, Kiemeney LA, Massuger LF, van Altena AM, Aben KK, Olson SH, Orlow I, Cramer DW, Levine DA, Bisogna M, Giles GG, Southey MC, Bruinsma F, Kjaer SK, Høgdall E, Jensen A, Høgdall CK, Lundvall L, Engelholm SA, Heitz F, du Bois A, Harter P, Schwaab I, Butzow R, Nevanlinna H, Pelttari LM, Leminen A, Thompson PJ, Lurie G, Wilkens LR, Lambrechts D, Van Nieuwenhuysen E, Lambrechts S, Vergote I, Beesley J; AOCS Study Group/ACS Investigators, Fasching PA, Beckmann MW, Hein A, Ekici AB, Doherty JA, Wu AH, Pearce CL, Pike MC, Stram D, Chang-Claude J, Rudolph A, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Bogdanova N, Antonenkova N, Odunsi K, Edwards RP, Kelley JL, Modugno F, Ness RB, Karlan BY, Walsh C, Lester J, Orsulic S, Fridley BL, Vierkant RA, Cunningham JM, Wu X, Lu K, Liang D, Hildebrandt MA, Weber RP, Iversen ES, Tworoger SS, Poole EM, Salvesen HB, Krakstad C, Bjorge L, Tangen IL, Pejovic T, Bean Y, Kellar M, Wentzensen N, Brinton LA, Lissowska J, Garcia-Closas M, Campbell IG, Eccles D, Whittemore AS, Sieh W, Rothstein JH, Anton-Culver H, Ziogas A, Phelan CM, Moysich KB, Goode EL, Schildkraut JM, Berchuck A, Pharoah PD, Sellers TA, Brooks-Wilson A, Cook LS, Le ND.

Mol Nutr Food Res. 2014 Oct;58(10):2023-35. doi: 10.1002/mnfr.201400068. Epub 2014 Jul 28.

35.

Moderate precision of prognostic scoring systems in a consecutive, prospective cohort of 544 patients with metastatic spinal cord compression.

Morgen SS, Nielsen DH, Larsen CF, Søgaard R, Engelholm SA, Dahl B.

J Cancer Res Clin Oncol. 2014 Dec;140(12):2059-64. doi: 10.1007/s00432-014-1776-2. Epub 2014 Jul 18.

PMID:
25035249
36.

ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.

Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J; Australian Ovarian Cancer Study Group, Williams RT, Flemming C, Lambrechts D, Despierre E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching P, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Nakanishi T, Yatabe Y, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan J, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut J, Iversen E, Weber RP, Berchuck A, Goode E, Bowtell DD, Chenevix-Trench G, deFazio A, Norris MD, MacGregor S, Haber M, Henderson MJ.

J Natl Cancer Inst. 2014 Jun 23;106(7). pii: dju149. doi: 10.1093/jnci/dju149. Print 2014 Jul.

37.

Prospective assessment of urinary, gastrointestinal and sexual symptoms before, during and after image-guided volumetric modulated arc therapy for prostate cancer.

Sveistrup J, Widmark A, Fransson P, Iversen P, Munck Af Rosenschöld P, Engelholm SA, Petersen PM.

Scand J Urol. 2015 Feb;49(1):58-69. doi: 10.3109/21681805.2014.913258. Epub 2014 May 5.

PMID:
24793783
38.

Hilgh Sensitivity and Specificity of PET/CT and Laparoscopic Diagnostic Lymph Node Excision for Lymph Node Metastases in Cervical Cancer Patients.

Hansen H, Loft A, Berthelsen AK, Lassen S, Høgdall C, Engelholm SA.

Pract Radiat Oncol. 2013 Apr-Jun;3(2 Suppl 1):S10. doi: 10.1016/j.prro.2013.01.034. Epub 2013 Mar 25. No abstract available.

PMID:
24674473
39.

Visual outcome after fractionated stereotactic radiation therapy of benign anterior skull base tumors.

Astradsson A, Wiencke AK, Munck af Rosenschold P, Engelholm SA, Ohlhues L, Roed H, Juhler M.

J Neurooncol. 2014 May;118(1):101-8. doi: 10.1007/s11060-014-1399-0. Epub 2014 Feb 15.

40.

Biomarkers for predicting complete debulking in ovarian cancer: lessons to be learned.

Fagö-Olsen CL, Ottesen B, Christensen IJ, Høgdall E, Lundvall L, Nedergaard L, Engelholm SA, Antonsen SL, Lydolph M, Høgdall C.

Anticancer Res. 2014 Feb;34(2):679-82.

PMID:
24510999
41.

Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance.

Sveistrup J, af Rosenschöld PM, Deasy JO, Oh JH, Pommer T, Petersen PM, Engelholm SA.

Radiat Oncol. 2014 Feb 4;9:44. doi: 10.1186/1748-717X-9-44.

42.

Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study.

Clausen MM, Hansen AE, Af Rosenschold PM, Kjaer A, Kristensen AT, McEvoy FJ, Engelholm SA.

Radiat Oncol. 2013 Nov 7;8:262. doi: 10.1186/1748-717X-8-262.

43.

Prognosis in patients with symptomatic metastatic spinal cord compression: survival in different cancer diagnosis in a cohort of 2321 patients.

Morgen SS, Lund-Andersen C, Larsen CF, Engelholm SA, Dahl B.

Spine (Phila Pa 1976). 2013 Jul 15;38(16):1362-7. doi: 10.1097/BRS.0b013e318294835b.

PMID:
23574811
44.

Diagnostic accuracy of risk of malignancy index in predicting complete tumor removal at primary debulking surgery for ovarian cancer patients.

Fagö-Olsen CL, Håkansson F, Antonsen SL, Høgdall E, Lundvall L, Nedergaard L, Engelholm SA, Høgdall C.

Acta Obstet Gynecol Scand. 2013 Jun;92(6):721-6. doi: 10.1111/aogs.12127. Epub 2013 Apr 9.

PMID:
23566210
45.

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.

Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE, Hillman KM, Mai PL, Lawrenson K, Stutz MD, Lu Y, Karevan R, Woods N, Johnston RL, French JD, Chen X, Weischer M, Nielsen SF, Maranian MJ, Ghoussaini M, Ahmed S, Baynes C, Bolla MK, Wang Q, Dennis J, McGuffog L, Barrowdale D, Lee A, Healey S, Lush M, Tessier DC, Vincent D, Bacot F; Australian Cancer Study; Australian Ovarian Cancer Study; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab); Gene Environment Interaction and Breast Cancer (GENICA); Swedish Breast Cancer Study (SWE-BRCA); Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON); Epidemiological study of BRCA1 & BRCA2 Mutation Carriers (EMBRACE); Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO), Vergote I, Lambrechts S, Despierre E, Risch HA, González-Neira A, Rossing MA, Pita G, Doherty JA, Alvarez N, Larson MC, Fridley BL, Schoof N, Chang-Claude J, Cicek MS, Peto J, Kalli KR, Broeks A, Armasu SM, Schmidt MK, Braaf LM, Winterhoff B, Nevanlinna H, Konecny GE, Lambrechts D, Rogmann L, Guénel P, Teoman A, Milne RL, Garcia JJ, Cox A, Shridhar V, Burwinkel B, Marme F, Hein R, Sawyer EJ, Haiman CA, Wang-Gohrke S, Andrulis IL, Moysich KB, Hopper JL, Odunsi K, Lindblom A, Giles GG, Brenner H, Simard J, Lurie G, Fasching PA, Carney ME, Radice P, Wilkens LR, Swerdlow A, Goodman MT, Brauch H, Garcia-Closas M, Hillemanns P, Winqvist R, Dürst M, Devilee P, Runnebaum I, Jakubowska A, Lubinski J, Mannermaa A, Butzow R, Bogdanova NV, Dörk T, Pelttari LM, Zheng W, Leminen A, Anton-Culver H, Bunker CH, Kristensen V, Ness RB, Muir K, Edwards R, Meindl A, Heitz F, Matsuo K, du Bois A, Wu AH, Harter P, Teo SH, Schwaab I, Shu XO, Blot W, Hosono S, Kang D, Nakanishi T, Hartman M, Yatabe Y, Hamann U, Karlan BY, Sangrajrang S, Kjaer SK, Gaborieau V, Jensen A, Eccles D, Høgdall E, Shen CY, Brown J, Woo YL, Shah M, Azmi MA, Luben R, Omar SZ, Czene K, Vierkant RA, Nordestgaard BG, Flyger H, Vachon C, Olson JE, Wang X, Levine DA, Rudolph A, Weber RP, Flesch-Janys D, Iversen E, Nickels S, Schildkraut JM, Silva Idos S, Cramer DW, Gibson L, Terry KL, Fletcher O, Vitonis AF, van der Schoot CE, Poole EM, Hogervorst FB, Tworoger SS, Liu J, Bandera EV, Li J, Olson SH, Humphreys K, Orlow I, Blomqvist C, Rodriguez-Rodriguez L, Aittomäki K, Salvesen HB, Muranen TA, Wik E, Brouwers B, Krakstad C, Wauters E, Halle MK, Wildiers H, Kiemeney LA, Mulot C, Aben KK, Laurent-Puig P, Altena AM, Truong T, Massuger LF, Benitez J, Pejovic T, Perez JI, Hoatlin M, Zamora MP, Cook LS, Balasubramanian SP, Kelemen LE, Schneeweiss A, Le ND, Sohn C, Brooks-Wilson A, Tomlinson I, Kerin MJ, Miller N, Cybulski C, Henderson BE, Menkiszak J, Schumacher F, Wentzensen N, Le Marchand L, Yang HP, Mulligan AM, Glendon G, Engelholm SA, Knight JA, Høgdall CK, Apicella C, Gore M, Tsimiklis H, Song H, Southey MC, Jager A, den Ouweland AM, Brown R, Martens JW, Flanagan JM, Kriege M, Paul J, Margolin S, Siddiqui N, Severi G, Whittemore AS, Baglietto L, McGuire V, Stegmaier C, Sieh W, Müller H, Arndt V, Labrèche F, Gao YT, Goldberg MS, Yang G, Dumont M, McLaughlin JR, Hartmann A, Ekici AB, Beckmann MW, Phelan CM, Lux MP, Permuth-Wey J, Peissel B, Sellers TA, Ficarazzi F, Barile M, Ziogas A, Ashworth A, Gentry-Maharaj A, Jones M, Ramus SJ, Orr N, Menon U, Pearce CL, Brüning T, Pike MC, Ko YD, Lissowska J, Figueroa J, Kupryjanczyk J, Chanock SJ, Dansonka-Mieszkowska A, Jukkola-Vuorinen A, Rzepecka IK, Pylkäs K, Bidzinski M, Kauppila S, Hollestelle A, Seynaeve C, Tollenaar RA, Durda K, Jaworska K, Hartikainen JM, Kosma VM, Kataja V, Antonenkova NN, Long J, Shrubsole M, Deming-Halverson S, Lophatananon A, Siriwanarangsan P, Stewart-Brown S, Ditsch N, Lichtner P, Schmutzler RK, Ito H, Iwata H, Tajima K, Tseng CC, Stram DO, van den Berg D, Yip CH, Ikram MK, Teh YC, Cai H, Lu W, Signorello LB, Cai Q, Noh DY, Yoo KY, Miao H, Iau PT, Teo YY, McKay J, Shapiro C, Ademuyiwa F, Fountzilas G, Hsiung CN, Yu JC, Hou MF, Healey CS, Luccarini C, Peock S, Stoppa-Lyonnet D, Peterlongo P, Rebbeck TR, Piedmonte M, Singer CF, Friedman E, Thomassen M, Offit K, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Garber J, Narod SA, Weitzel JN, Montagna M, Olah E, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Imyanitov EN, Tihomirova L, Arun BK, Campbell I, Mensenkamp AR, van Asperen CJ, van Roozendaal KE, Meijers-Heijboer H, Collée JM, Oosterwijk JC, Hooning MJ, Rookus MA, van der Luijt RB, Os TA, Evans DG, Frost D, Fineberg E, Barwell J, Walker L, Kennedy MJ, Platte R, Davidson R, Ellis SD, Cole T, Bressac-de Paillerets B, Buecher B, Damiola F, Faivre L, Frenay M, Sinilnikova OM, Caron O, Giraud S, Mazoyer S, Bonadona V, Caux-Moncoutier V, Toloczko-Grabarek A, Gronwald J, Byrski T, Spurdle AB, Bonanni B, Zaffaroni D, Giannini G, Bernard L, Dolcetti R, Manoukian S, Arnold N, Engel C, Deissler H, Rhiem K, Niederacher D, Plendl H, Sutter C, Wappenschmidt B, Borg A, Melin B, Rantala J, Soller M, Nathanson KL, Domchek SM, Rodriguez GC, Salani R, Kaulich DG, Tea MK, Paluch SS, Laitman Y, Skytte AB, Kruse TA, Jensen UB, Robson M, Gerdes AM, Ejlertsen B, Foretova L, Savage SA, Lester J, Soucy P, Kuchenbaecker KB, Olswold C, Cunningham JM, Slager S, Pankratz VS, Dicks E, Lakhani SR, Couch FJ, Hall P, Monteiro AN, Gayther SA, Pharoah PD, Reddel RR, Goode EL, Greene MH, Easton DF, Berchuck A, Antoniou AC, Chenevix-Trench G, Dunning AM.

Nat Genet. 2013 Apr;45(4):371-84, 384e1-2. doi: 10.1038/ng.2566.

46.

Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.

Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J, Souami F, Wing P, Engelholm S, Bamias A, Schwartz P.

J Clin Oncol. 2012 Nov 1;30(31):3841-7. doi: 10.1200/JCO.2011.38.8082. Epub 2012 Sep 17.

PMID:
22987083
47.

Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.

Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.

Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24.

PMID:
22835718
48.

Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer.

Risum S, Loft A, Engelholm SA, Høgdall E, Berthelsen AK, Nedergaard L, Lundvall L, Høgdall C.

Int J Gynecol Cancer. 2012 Sep;22(7):1163-9.

PMID:
22810969
49.

(64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry.

Hansen AE, Kristensen AT, Jørgensen JT, McEvoy FJ, Busk M, van der Kogel AJ, Bussink J, Engelholm SA, Kjær A.

Radiat Oncol. 2012 Jun 15;7:89. doi: 10.1186/1748-717X-7-89.

50.

Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass.

Håkansson F, Høgdall EV, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Høgdall C; DANISH ‘PELVIC MASS’ OVARIAN CANCER STUDY.

Acta Obstet Gynecol Scand. 2012 Apr;91(4):496-502. doi: 10.1111/j.1600-0412.2012.01359.x. Epub 2012 Feb 22.

PMID:
22229703

Supplemental Content

Loading ...
Support Center